Literature DB >> 14695212

Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.

Takeshi Terui1, Ken Murakami, Rishu Takimoto, Minoru Takahashi, Koichi Takada, Tsuzuku Murakami, Shinya Minami, Takuya Matsunaga, Tetsuji Takayama, Junji Kato, Yoshiro Niitsu.   

Abstract

Two controversial issues regarding p53 are whether it is involved in apoptosis induction of tumor cells by a histone deacetylase (HDAC) inhibitor and, given that p53 is indeed involved, which genes of acetylated p53 targets are responsible for giving rise to apoptotic death. We, in the present study, first confirmed that some substantial extent of apoptotic cell death was seen when p53-deficient cells (KATO-III) were transfected with wild-type p53 and treated with sodium butyrate (SB) or trichostatin A. By Western blotting, using specific antibodies, we then demonstrated that residues 320, 373, and 382 lysines of p53 were acetylated in KATO-III cells transfected with wild-type p53 (KATO-III/p53) treated with a HDAC inhibitor. However, as revealed by terminal deoxynucleotidyl transferase-mediated nick end labeling staining, only those KATO-III cells transfected with K320R p53 or K373R p53 became insensitive to the HDAC inhibitor, suggesting that these two residues of p53 may be essential for HDAC inhibitor-induced apoptosis, whereas others such as K382R p53 may not. Furthermore, reverse transcription-PCR demonstrated that among various p53-related proapoptotic genes, expression of PIG3 and NOXA were clearly enhanced by SB treatment in KATO-III/p53 cells but not in KATO-III/K320R or KATO-III/K373R cells. Finally, we revealed that apoptosis could be evoked by SB even in cells where p53 mutations occur at residues other than 320 lysine or 373 lysine (TMK-1 and HSC-39 cells) and that this apoptosis was significantly, although not totally, suppressed by the anti-p53 antisense. It was, therefore, concluded that acetylation of the p53 molecule at residues 320 and 373, giving rise to up-regulation of PIG3 and NOXA, is one of the mechanisms for induction of apoptosis by HDAC inhibitors in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

2.  Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage.

Authors:  Connie Chao; Zhiqun Wu; Sharlyn J Mazur; Helena Borges; Matteo Rossi; Tongxiang Lin; Jean Y J Wang; Carl W Anderson; Ettore Appella; Yang Xu
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.

Authors:  Takuma Uo; Timothy D Veenstra; Richard S Morrison
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

4.  FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.

Authors:  Updesh Dixit; Ashutosh K Pandey; Zhihe Liu; Sushil Kumar; Matthew B Neiditch; Kenneth M Klein; Virendra N Pandey
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage.

Authors:  A Vashishta; M Hetman
Journal:  Neuromolecular Med       Date:  2014-07-26       Impact factor: 3.843

Review 6.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

7.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Authors:  R K Lindemann; A Newbold; K F Whitecross; L A Cluse; A J Frew; L Ellis; S Williams; A P Wiegmans; A E Dear; C L Scott; M Pellegrini; A Wei; V M Richon; Paul A Marks; S W Lowe; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 8.  The emerging role of lysine acetylation of non-nuclear proteins.

Authors:  Pierre Close; Catherine Creppe; Magali Gillard; Aurélie Ladang; Jean-Paul Chapelle; Laurent Nguyen; Alain Chariot
Journal:  Cell Mol Life Sci       Date:  2010-01-16       Impact factor: 9.261

9.  Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.

Authors:  M T de Bruijn; D A E Raats; F J H Hoogwater; W J van Houdt; K Cameron; J P Medema; I H M Borel Rinkes; O Kranenburg
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

10.  The transcriptional co-activator PCAF regulates cdk2 activity.

Authors:  Francesca Mateo; Miriam Vidal-Laliena; Núria Canela; Annalisa Zecchin; Marian Martínez-Balbás; Neus Agell; Mauro Giacca; María Jesús Pujol; Oriol Bachs
Journal:  Nucleic Acids Res       Date:  2009-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.